2025
EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES. Urologic Oncology Seminars And Original Investigations 2025, 43: 43. DOI: 10.1016/j.urolonc.2024.12.109.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaNational Cancer DatabaseMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalImpact of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsPrimary treatment typeCox proportional hazards analysisSite of metastasisEvaluate clinical outcomesProportional hazards analysisBorderline statistical significancePT0 rateOS benefitHistological subtypesCancer DatabaseClinical stageClinical outcomesTreatment patternsCurrent therapiesInstitutional experiencePrimary outcome
2023
Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.
Tripathi A, Tangen C, Li X, Tretiakova M, Humphrey P, Adeniran A, Barata P, Gulati S, Bergerot C, Pruthi D, Thompson I, Lara P, Pal S, Shuch B. Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial. Journal Of Clinical Oncology 2023, 41: 4562-4562. DOI: 10.1200/jco.2023.41.16_suppl.4562.Peer-Reviewed Original ResearchProgression-free survivalPositive predictive valueCentral pathology reviewCentral reviewPathology reviewHistologic subtypeType 1PRCC subtypesAdvanced papillary renal cell carcinomaPathologic concordance rateLines of therapyPapillary renal cell carcinomaSubset of patientsType 2 tumorGreater clinical benefitRenal cell carcinomaLimited clinical valueType 2 diseaseExpert genitourinary pathologistsLocal reviewClassification of subtypesSunitinib armMET alterationsClinical outcomesClinical benefit
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply